| DelMar Pharmaceuticals is a clinical stage, biopharmaceutical company. Co. is developing VAL-083, a DNA-targeting agent, for the treatment of drug-resistant solid tumors such as glioblastoma multiforme (GBM) and other solid tumors, including ovarian cancer and non-small cell lung cancer. Co. is also conducting open-label, biomarker driven studies in methyl guanine methyltransferase-unmethylated GBM. In addition to its clinical development activities in the United States, Co. has provided Guangxi Wuzhou Pharmaceutical (Group) Co. Ltd. certain commercial rights to VAL-083 in China where it is approved as a chemotherapy for the treatment of chronic myelogenous leukemia and lung cancer. We show 18 historical shares outstanding datapoints in our DMPI shares outstanding history coverage, used to compute DMPI market cap on those dates.|
Understanding the changing numbers of shares outstanding, the changing
share price, and the resulting changing DMPI market cap history over the course of time is important for investors
interested in comparing DMPI's market cap history versus its peers.
Many "beginner" or "novice" investors will look at one stock trading at a price of $10 per share and another trading at
a price of $20 per share and think the latter company is worth twice as much. Of course, that is a completely meaningless comparison without also knowing how many shares outstanding there are for each of the two companies,
and then calculating their respective market caps. Comparing the share price of DMPI versus a peer is one thing; comparing
DMPI market cap versus a peer is a completely different story.
Furthermore, via fluctuation both in per-share price and in the number of shares outstanding (via issuance of new shares over time, the repurchase of existing shares),
the market cap for a company like DMPI can fluctuate over the course of history.
With this page we aim to empower investors researching DMPI by allowing them to research the DMPI market cap history.